India- Inching Towards a $100 Bn Bio-Manufacturing Hub
India is among the Top 12 destinations for biotechnology worldwide and 3rd largest destination for biotechnology in Asia Pacific. In 2022, India’s Biotechnology industry has crossed US$80.12 Bn, growing 14% from the previous year. The Indian BioEconomy has witnessed a manyfold increase in valuation in the past ten years, with COVID-19 giving the industry a much needed push. Today, India is poised as one of the leading destinations for bioinnovation and biomanufacturing, and hence is identified as a sunrise sector and a key part of India’s vision of reaching a US$5 Tn Economy by 2024. India’s Biotechnology sector is categorised into BioPharmaceuticals, Bioagriculture, BioIT and BioServices.
BioPharmaceuticals: India is one of the biggest suppliers of low cost drugs and vaccines in the world. India also leads in biosimilars, with the most number of biosimilars approved in the domestic market.
BioAgriculture: With nearly 55% of Indian terrain under agriculture and allied activities, India is one of largest producer of Bt-Cotton and has the 5th Largest Area of Organic Agriculture Land Globally.
BioIndustrial: The application of biotechnology to industrial processes is transforming manufacturing and waste disposal across the country.
BioIT & Services: India offers a strong capability in contract manufacturing, research and clinical trials, and is home to the most US FDA approved plants globally outside of the US.
- Forecasted to reach $150 Bn by 2025, and $300 Bn by 2030 with a CAGR of ~17%
- 5300+ biotech startups, estimated to reach 10000 by 2025
- 760+ biotech companies
- 750+ Biotech Products in market
- 1Mn+ skilled biotech workforce
- 4th Largest Ethanol Producer
- 5th Largest Area of Organic Agriculture Land Worldwide
- 7th Largest Destination for Clinical Trials
100% FDI is allowed under the automatic route for greenfield pharma.
100% FDI is allowed under the government route for brownfield pharma. Upto 74% FDI is under automatic route and beyond 74% is under the government approval route.
FDI up to 100% is allowed under the automatic route for the manufacturing of medical devices.
For further details, please refer FDI Policy
Growth Over the last decade
Expected CAGR (2022-2025)
- $ Bn
R&D Expenditure in Biotech
Largest Supplier of DPT, Measles and BCG Vaccines
Developed World’s First DNA Vaccine Against COVID-19
World's highest number of USFDA Approved Manufacturing Plants Outside the USA.
- Industry Scenario
- FOREIGN INVESTMENT
- INDUSTRY TRENDS
- POLICIES & SCHEMES
Valued at $ 80.12 Bn in 2022, the Indian Biotechnology Industry is targeted to reach $ 150 Bn by 2025 and $ 300 Bn by 2030.
The growth of the Indian biotechnology sector is fuelled by rising demand at both a domestic and international levels. The rise in domestic demand is fuelled by intiatives such as Aatmanirbhar Bharat and Make In India, while overseas demand for Indian vaccines and biopharmaceuticals is due to the globally competitive efficacy of Indian products. India exports vaccines to over 150 countries and is a leading destination for contract manufacturing and clinical trials. In order to contain healthcare costs, companies are leveraging generics and biosimilars, and India has poised itself as a hub to deliver affordable access to innovative and inclusive healthcare solutions.
- The percentage share of the biotechnology segments is:
- BioPharmaceuticals- 68%
- Diagnostics- 33%
- Therapeutics- 13%
- Vaccines- 22%
- Bt-Cotton- 12%
- BioFertilisers, BioPesticides & BioStimulants- 1%
- BioIndustry- 12%
- BioFuels- 7%
- Enzymes- 5%
- BioIT & BioServices- 7%
1Mn+ Skilled Biotech Workforce; Pan India Star College Mentorship Program by DBT
74 Bio-incubation Centers created through DBT-BIRAC and 4 Industry Clusters in Kalyani, Pune, Bangalore, Delhi NCR
Government acting as an enabler to improve EoDB
Critical Policy initiatives such as 'Make in India’, ‘Startup India’, ‘Atmanirbhar Bharat Abhiyan’ (boosting domestic manufacturing capacity) and formulation of the National Biotechnology Development Strategy 2021-25.
Focus on Research & Development
Favorable Government Policies like Draft R&D Policy 2021, PLI Schemes and Clinical trial rules have propelled India to be the ‘pharmacy of the world’. India has invested $ 1 Bn in biotechnology R&D in 2022.
Increasing Population and Lifestyle Changes; Government expenditure on healthcare up to 2.1% of GDP in FY21-22, with a target of 2.5% of the country's GDP by 2025